Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Steroidal mineralocorticoid receptor antagonists reduce morbidity and mortality among patients with heart failure and reduced ejection fraction, but their efficacy in those with heart failure and mildly reduced or preserved ejection fraction has not been established. Data regarding the efficacy and safety of the nonsteroidal mineralocorticoid receptor antagonist finerenone in patients with heart failure and mildly reduced or preserved ejection fraction are needed. METHODS: In this international, double-blind trial, we randomly assigned patients with heart failure and a left ventricular ejection fraction of 40% or greater, in a 1:1 ratio, to receive finerenone (at a maximum dose of 20 mg or 40 mg once daily) or matching placebo, in addition to usual therapy. The primary outcome was a composite of total worsening heart failure events (with an event defined as a first or recurrent unplanned hospitalization or urgent visit for heart failure) and death from cardiovascular causes. The components of the primary outcome and safety were also assessed. RESULTS: Over a median follow-up of 32 months, 1083 primary-outcome events occurred in 624 of 3003 patients in the finerenone group, and 1283 primary-outcome events occurred in 719 of 2998 patients in the placebo group (rate ratio, 0.84; 95% confidence interval [CI], 0.74 to 0.95; P = 0.007). The total number of worsening heart failure events was 842 in the finerenone group and 1024 in the placebo group (rate ratio, 0.82; 95% CI, 0.71 to 0.94; P = 0.006). The percentage of patients who died from cardiovascular causes was 8.1% and 8.7%, respectively (hazard ratio, 0.93; 95% CI, 0.78 to 1.11). Finerenone was associated with an increased risk of hyperkalemia and a reduced risk of hypokalemia. CONCLUSIONS: In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone resulted in a significantly lower rate of a composite of total worsening heart failure events and death from cardiovascular causes than placebo. (Funded by Bayer; FINEARTS-HF ClinicalTrials.gov number, NCT04435626.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Over the past decade, the use of medications that have been demonstrated to be effective in patients with HF with reduced ejection fraction (angiotensin receptor neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 [SGLT2] inhibitors) has been evaluated in large-scale trials in patients with HF and mildly reduced ejection fraction and patients with HFpE”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“This level was significantly lower than that in the STEP-HFpEF program (median, ≈470 pg/mL)36 and substantially lower than in other large-scale outcome trials in HFpEF (median 900–1400 pg/mL).3–6”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Of the enrolled participants, 41% had type 2 diabetes.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [303]
The cited source says what the claim attributes to it.
In the citing paper
“The selective nonsteroidal MRA finerenone was examined in the Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% (FINEARTS-HF) trial of people with symptomatic HFpEF (ejection fraction ≥40%) and was found to reduce the risk of”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [303]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Self-citationPitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Self-citationEmpagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Self-citationEplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationDapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206286 · Cited by 2,884
Self-citationSpironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809
Self-citationAngiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908655 · Cited by 2,430
Self-citationSotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Self-citationCardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Self-citation
Cited by
Items 501–600 of 892
Mineralocorticoid inhibition in heart failure: does one size fit all?
Brown, J. M., & Cunningham, J. W. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag603 · Cited by 1
Ruppert, M., Vaduganathan, M., Claggett, B. L., Desai, A. S., Jhund, P. S., Henderson, A. D., Lay‐Flurrie, J., BRINKER, M. D., Hofmeister, L. H., Anker, M. S., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag522 · Cited by 2
Self-citationSu, J., Zhao, Y., Coleman, P., Yang, X., Holt, M., Raabe, J., Cuello, F., Shah, A. M., Shattock, M. J., Zhang, M., et al. (2026) · Science Advances · doi:10.1126/sciadv.aec8088 · Cited by 1
HFpEF-ABA Score for the Diagnosis and Prognosis of HFpEF in Outpatients With Type 2 Diabetes
Manzanares, R. G., Anguita, M., Muñiz, J., Barrios, V., Gimeno-Orna, J. A., Pérez, A., Rodríguez-Padial, L., & Gámez, M. A. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.103196 · Cited by 1
Inflammation as a therapeutic target to improve kidney and cardiovascular outcomes
Tuttle, K. R., Kanbay, M., Alicic, R. Z., Carrero, J. J., Çöpür, S., Navar, A. M., Neuen, B. L., Perkovic, V., Rossing, P. R., Marx, N., et al. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01117-6 · Cited by 4
“The ns-MRA, finerenone, is a GDMT for patients with type 2 diabetes and CKD 184,202 that also improves heart failure outcomes in individuals with HFpEF or heart failure with mildly reduced ejection fraction 203 .”
Patoulias, D., Karagiannidis, E., Maragkoudakis, S., Alexanian, I. P., Papadopoulos, C., & Fragakis, N. (2026) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2026.08.007 · Cited by 1
Lund, L. H., Lam, C. S. P., Pizzato, P. E., Michaëlsson, E., Mattsson, A., Ericsson, H., Aurell, M., Collén, A., Trebski, M., Whatling, C. A., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04615-z · Cited by 2
Self-citationTokodi, M., Kagiyama, N., Pandey, A., Nakamura, Y., Akama, Y., Takamatsu, S., Toki, M., Kitai, T., Okada, T., Lam, C. S. P., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.103115 · Cited by 1
Self-citationDavies, M. J., Aroda, V. R., Bajaj, M. S., ElSayed, N. A., Giorgino, F., Green, J., Kalyani, R. R., Maruthur, N. M., Mathieu, C., Rosas, S. E., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06855-7 · Cited by 1
HAJDUCZOK, A. G., DONALD, E. M., Maning, J., Youmans, Q. R., & Reza, N. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.10.001 · Cited by 1
What’s New in Heart Failure? October 2024
Lee, M. M. Y., Codina, P., Tomasoni, D., & Aimo, A. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3492 · Cited by 1
Komiyama, M., Hasegawa, K., & Rosano, G. M. C. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae082 · Cited by 1
Prospective registry of heart failure with preserved ejection fraction in México: EDIFICE-Mx
Garaygordobil, D. A., Preciado-Gutiérrez, Ó. U., Martinez, J. D. S.-L., González‐Pacheco, H., Gopar‐Nieto, R., Esparza, X. L. R., Pastrana, S. H., Diaz-Herrera, B. A., Álvarez‐Sangabriel, A., Jordán‐Ríos, A., et al. (2024) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2024.100486 · Cited by 3
Between Scylla and Charybdis: Navigating heart failure management in complex older adults
der Linden, L. R. V., & Tsuyuki, R. T. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16357 · Cited by 2
Insuficiência Cardíaca no Brasil: Como Podemos Melhorar sua História Natural?
Ferrari, F., Rossi, A. P., & Santander, I. R. M. F. (2024) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20240644 · Cited by 1
Acute cardiovascular care 2024 in review: acute heart failure
Platz, E., Aleksić, M., & Verbrugge, F. H. (2024) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuae145 · Cited by 1
Disease modifying therapies in heart failure: an update
Tanaka, A., & Node, K. (2025) · QJM · doi:10.1093/qjmed/hcaf060 · Cited by 3
Sodium-glucose co-transporter 2 inhibitors in acute heart failure: What are you waiting for?
Morillas, H., & Colet, J. C. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.03.002 · Cited by 1
Silva‐Cardoso, J., Moreira, E., de Melo, R. T., Sarmento, P., Cardim, N. M., Oliveira, M., Gavina, C., Moura, B., Araújo, I., Santos, P. R., et al. (2025) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2024.12.004 · Cited by 4
Self-citationAlbuminuria Range as a Key Metric Linking Renal Function to Heart Failure Outcome in FINEARTS-HF
Gronda, E., Arduini, A., Iacoviello, M., Carugo, S., & Tavazzi, L. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.12.036 · Cited by 1
Ueda, T., Kuwahara, K., Hiramitsu, S., Onishi, K., Yumino, D., Seno, A., Shiino, K., Nogi, M., Isogawa, M., Kawamoto, A., et al. (2025) · Circulation Reports · doi:10.1253/circrep.cr-24-0138 · Cited by 2
Walsh, M. W., Collister, D., Gallagher, M., Mark, P. B., de Zoysa, J., Tyrwhitt, J., Tennankore, K., Solá, L., Reis, G., Xavier, D., et al. (2025) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581251348187 · Cited by 6
Samankan, S., & Entezari‐Maleki, T. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.1530 · Cited by 1
Less Heart Failure But No Improvement in Quality of Life in FINEARTS-HF
Cotter, G., Davison, B. A., & Bhatt, D. L. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.04.022 · Cited by 1
Noverraz, V., Carballo, S., Carballo, D., Philippe, M., & Garin, N. (2025) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2025.101723 · Cited by 1
“Though several medications are strongly recommended with high levels of evidence in HFrEF [1], only SGLT2 inhibitors and mineralocorticoid receptor antagonists such as finerenone convincingly modify the course of disease in HFpEF [4].”
InfluentialHeart Failure with Preserved Ejection Fraction in the Indian Context
Gupta, R., Choudhary, M., & Guptha, S. (2025) · Journal of Indian College of Cardiology · doi:10.4103/jicc.jicc_65_24 · Cited by 1
Hsieh, M., Lee, C., Chen, D., Wu, C.-L., & Chang, S. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.08.327 · Cited by 1
Heart Failure with Preserved Ejection Fraction
Matthews, E. (2025) · AJN American Journal of Nursing · doi:10.1097/ajn.0000000000000184 · Cited by 3
Kim, B., Bae, S., Kim, S. J., Im, S. I., & Heo, J.-H. (2025) · Kosin Medical Journal · doi:10.7180/kmj.25.124 · Cited by 1
Advances and Challenges in Holistic Treatment of Cardiometabolic Kidney Disease as One Entity
Bozkurt, B. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.10.002 · Cited by 2
Wu, J., Biswas, D., Brown, S., Ryan, M., Bernstein, B. S., To, B. T., Searle, T., Rizvi, M., Fairhurst, N., Kaye, G., et al. (2024) · medRxiv · doi:10.1101/2024.12.24.24319603 · Cited by 1
Ending the Fear Depriving Patients With HFpEF and CKD of Lifesaving Therapies
Costanzo, M. R. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2024.09.020 · Cited by 1
Unentangling Heart Failure From Kidney Outcomes With Finerenone
Kaul, S., & Hiremath, S. S. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.024 · Cited by 1
When Kidney Function Declines But Therapy Still Works
Damman, K. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.12.002 · Cited by 1
Symptomatic Improvement “Only” in Unblinded Trials
Levy, A. M., Singh, J., & Stone, G. W. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.045 · Cited by 1
Effect of Finerenone Across the Stages of Heart Failure: From Prevention to Treatment
Biegus, J., Palazzuoli, A., & Greene, S. J. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3606 · Cited by 1
Ubiquity of Multimorbidity: Comorbid Conditions and Mortality in HFpEF
Kamat, I., & Nair, A. P. (2025) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.012432 · Cited by 1
Reply to: Finerenone in the SGLT2i era: redundancy or complementarity?
Hakim, J. P. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156338 · Cited by 1
Kudaiberdieva, G. (2024) · Heart Vessels and Transplantation · doi:10.24969/hvt.2024.510
European Society of Cardiology Congress 2024 Meeting: Heart Failure Highlights
DONALD, E. M., HAJDUCZOK, A. G., & CAMPBELL, P. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.09.001
Lindberg, F., & Savarese, G. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.09.022
Pliças, M. M. D., da Silva, B. M., & Almeida, E. (2024) · Nefrología · doi:10.1016/j.nefro.2024.10.004
Macklin, L., & Simpson, M. (2024) · European Journal of Cardiovascular Nursing · doi:10.1093/eurjcn/zvae140
Interpreting Health Status Measures in Patients With Heart Failure—What Counts
Udelson, J. E., Yancy, C. W., & Fonarow, G. C. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2024.4610
Evolution in the Definition of Stages in HFpEF and Its After-Effect
Gelfman, D. M. (2024) · The American Journal of Medicine · doi:10.1016/j.amjmed.2024.11.008
Sex-Specific Efficacy and Safety in HF Trials
Khan, S. S., Yancy, C. W., & Fonarow, G. C. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2024.4624
The Fine Art and Science of Translating Trials Results Into Clinical Practice
Fonarow, G. C., Peterson, E. D., & Hernandez, A. F. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2024.4550
Lanthier, L., Mutchmore, A., Plourde, M.-É., & Cauchon, M. (2024) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2024.11.007
Effect of eplerenone in acute heart failure using a win ratio approach
Kobayashi, M., Yamashina, A., Satomi, K., Tezuka, A., Duarte, K., Ito, S., Asakura, M., Kitakaze, M., & Girerd, N. (2024) · Clinical Research in Cardiology · doi:10.1007/s00392-024-02578-0
Is It Primetime for Finerenone in Heart Failure?
Dixit, N. M., & Schaefer, S. (2024) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.012530
The Family Physician’s Unique Role in Heart Failure Management
Chua, G. L. (2024) · Canadian Primary Care Today · doi:10.58931/cpct.2024.2335
Another Note of Caution for Spironolactone: Implications of the BARACK-D Study
Kumar, A. U., & Rifkin, D. E. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2024.12.002 · Cited by 1
Pharmacotherapy of chronic heart failure - essential summary for pharmacists
Monhart, Z. (2025) · Česká a slovenská farmacie · doi:10.36290/csf.2024.039
Finerenone: Completing the Cardiorenal Guideline-Directed Medical Therapy?
Khosravi, Z., Iqbal, M., & Kant, S. (2025) · Kidney News · doi:10.62716/kn.000332024
Halving heart failure outcomes by finerenone-mediated type 2 diabetes prevention
Gerstein, H. C., & Mohammedi, K. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00317-6
A Comprehensive Exploration of FINEARTS-HF
Krumholz, H. M., & McDonagh, T. A. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.12.004
Maning, J., Lala, A., & Mentz, R. J. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.12.003
Marx-Schütt, K., Kintscher, U., Dahm, J. B., Fliser, D., Heine, G. H., Hoyer, J. D., Jung, C., Mahfoud, F., Ott, I., Schlieper, G., et al. (2025) · Die Kardiologie · doi:10.1007/s12181-024-00716-6
Finerenone in Heart Failure with Preserved Ejection Fraction
Pedreira-Bouzas, J., Pousada-Fonseca, Á., & Sierra-Sánchez, J. F. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2414955
Simple and Practical Way of Assessing Diastolic Function: Diastolic Heart Failure Revisited
Sohn, D. (2025) · Korean Circulation Journal · doi:10.4070/kcj.2025.0005
“23) Similar to the results of TOPCAT study, finerenone showed positive result in the primary endpoint but did not reduce cardiovascular death.”
Liuzzo, G., & Patrono, C. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf013
Bewährtes und Neues in der Therapie der Herzinsuffizienz
Schwenger, V. (2025) · Die Nephrologie · doi:10.1007/s11560-024-00821-3
To Be, or Not to Be: Is It Better to Be HFrEF or HFpEF or Somewhere In Between (HFmrEF)?
Bartels, S., Lee, R., & Kwak, J. (2025) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2025.02.016
Mitigating heart failure risk in patients with diabetes and chronic kidney disease
Kowalczyk, N. S., & Prochaska, M. (2025) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001208
“In recent years, ns-MRA, have been shown to reduce the risk of CKD progression and cardiovascular risk (Table 1) [38,40 & ].”
Atrial Fibrillation and Heart Failure
Kusumoto, F. M. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.01.004
Precision Medicine Is in the Eye of the Beholder
Margulies, K. B. (2025) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.012759
Obesity and heart failure—the role of GLP-1 receptor agonists
Simonis, G., & Schatz, U. (2025) · Herz · doi:10.1007/s00059-025-05312-2
Device-based therapies for heart failure with preserved ejection fraction
Kim, R., Kittipibul, V., Bhatt, S., & Fudim, M. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10510-5 · Cited by 1
Weekly Journal Scan: a deep insight into aldosterone antagonism across the heart failure spectrum
Pedicino, D., & Volpe, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf233
Traitement pharmacologique de l’insuffisance cardiaque
Logeart, D. (2025) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2025.03.002
A comprehensive review of inpatient heart failure management for the hospitalist
Rajesh, A., Kovacik, R., Wasef, B., Lohr, K., & Kasprowicz, E. (2025) · Postgraduate Medicine · doi:10.1080/00325481.2025.2503696
“Similarly, the FINEARTS trial showed that finerenone treatment led to a significant reduction in a composite of worsening heart failure events and cardiovascular death in comparison to placebo in patients with HFmrEF or HFpEF [58].”
ANMCO position paper: diagnosis and treatment of heart failure with preserved systolic function
Iacovoni, A., Navazio, A., Luca, L. D., Gori, M., Corda, M., Milli, M., Iacoviello, M., Lenarda, A. D., Tano, G. D., Marini, M., et al. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suaf070
Self-citationHerz und Diabetes – Was gibt es Neues?
Marx-Schütt, K. (2025) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2349-9962
Receptor activation via phase separation affects cardiac preservation quality
(2025) · Nature Cardiovascular Research · doi:10.1038/s44161-025-00668-4
Wolf, P. J. W., Correia, E. B., Neto, J. M. R., Finger, M. A., dos Santos, C. C., Vasconcellos, M. D. O., Bruscky, L. V. R., Murta, A. C. D. S., Francisco, Y. A., Albrecht, F. C., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20240676 · Cited by 8
High-Complexity Questions and Their Answers for Everyday Heart Failure
de Santamaría, A. C. S., Pérez-Santana, J., Croset, F., Esterellas-Sánchez, L. K., Lobo-Antuña, V., Martínez, M. R., Botero, S. N. R., Sacristán, H. G., Pérez-Silvestre, J., Rodríguez, J. M. F., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113993
“• FINEARTS [5–7]: The recent FINEARTS-HF study evaluated the effect of finerenone in HF with preserved or mildly reduced EF (EF ≥ 40%).”
Editorial commentary: Finerenone as an additional therapeutic strategy in heart failure
Larroux, B., & Bonaventura, A. (2025) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2025.06.001
Time to Rethink our Approach to Guidelines? International Cascade Guidelines for Heart Failure
Atherton, J. J., Sindone, A. P., & Coats, A. J. S. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.05.093
Self-citationDocumento de consenso para el diagnóstico y tratamiento de la insuficiencia renal aguda
Ramos-Terrades, N., Benítez, P. R., Gallardo, J. M. U., Valdenebro, M., Salgueira, M., Andújar, A. M., Martins, J., Ramos-Galí, A., Moreno, J. A., Cuerda, C., et al. (2025) · Nefrología · doi:10.1016/j.nefro.2025.501360
Agarwal, R. (2025) · Kidney International · doi:10.1016/j.kint.2025.03.010
Advances in the treatment of heat failure
Málek, F. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.047
Protocolo terapéutico de la insuficiencia cardíaca con fracción de eyección conservada
Morán, J. S., Romo, E. G., Barros, A. L., González, C. T., Ruiz-Saavedra, A., & Lledó, A. G. (2025) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2025.06.015
Insuficiencia cardíaca crónica con fracción de eyección del ventrículo izquierdo conservada
Morán, J. S., Romo, E. G., Barros, A. L., Ruiz-Saavedra, A., González, C. T., & Lledó, A. G. (2025) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2025.06.012
Abbate, A. (2025) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001733
Pivotal Trials in Heart Failure in 2024—Putting Evidence into Clinical Practice!
Thandi, P., Pradhan, A. K., & Behera, S. K. (2025) · International Journal of Angiology · doi:10.1055/a-2624-5735
Dressler, D. D. (2025) · Medical Clinics of North America · doi:10.1016/j.mcna.2025.05.011
Sun, J., Wang, T., Yi, Y., Ye, T., Shao, J., & Du, Y. (2025) · Statistics in Medicine · doi:10.1002/sim.70187
“Incorporating prognostic baseline covariates into the design and analysis of clinical trial data can improve the efficiency of data utilization, leading to more precise estimation and demonstration of treatment effects [11, 12].”
The Role of Medical Therapy in Hypertrophic Cardiomyopathy
Lee, J.-W., Chun, K., Choi, E., & Seo, J. (2025) · Heart Failure Clinics · doi:10.1016/j.hfc.2025.06.005
He, J., Chen, G., Huo, Y., Zhang, C., Xue, H., Wang, J., Zhong, Y., Xiao, J., Shen, H., & Feng, J. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1564860
Earl, J. C., Hart, L. A., & Hansen, R. N. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.31.8.741
"Youth Is a Disease that is Cured with Age"
Lerman, J. (2025) · Revista Argentina de Cardiología · doi:10.7775/rac.v93.i3.20895
Lederer, E. D. (2025) · Nephrology Self-Assessment Program · doi:10.58483/nsap.00382025
Ilany, J., Cohen, O., & Gorfine, M. (2025) · Research Square · doi:10.21203/rs.3.rs-6863965/v1
Heart Failure in 2025: Update With Perioperative Considerations
Mendapara, P., Ramakrishna, H., & Stawiarski, K. M. (2025) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2025.08.019 · Cited by 1
Umahashi, M., Sazanami, K., Horiuchi, N., Dote, S., & Kobayashi, Y. (2025) · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · doi:10.5649/jjphcs.51.498
Docherty, K. F., Henderson, A. D., Jhund, P. S., Solomon, S. D., & McMurray, J. J. V. (2025) · Circulation · doi:10.1161/circulationaha.125.075278
Self-citationIntegrating and Simplifying Evidence to Optimize Cardiorenal Guideline-Directed Therapies
Singh, H., Puckett, C., & Lucas, Y. Q. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14165883
“Similarly, in the Finerenone in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF) trial [26] evaluating finerenone versus a placebo, an initial eGFR reduction was noted with finerenone; however, the long-term eGFR slopes were nearly parallel between the…”
What's New in Heart Failure? July 2025
Markwirth, P., Hoevelmann, J., Tokcan, M., & Haring, B. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70007 · Cited by 1
Cherbi, M., Roubille, F., Gautier, P., Puymirat, É., Elbaz, M., Bonello, L., Lamblin, N., Bonnefoy‐Cudraz, E., & Delmas, C. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02741-1 · Cited by 1
Metadata
- Authors
- Solomon, S. D., McMurray, J. J. V., Vaduganathan, M., Claggett, B., Jhund, P. S., Desai, A. S., Henderson, A. D., Lam, C. S. P., Pitt, B., Senni, M., Shah, S. J., Voors, A. A., Zannad, F., Abidin, I. Z., Alcocer-Gamba, M. A., Atherton, J. J., Bauersachs, J., Chang-Sheng, M., Chiang, C.-E., Chioncel, O., Chopra, V., Comin-Colet, J., Filippatos, G., Fonseca, C., Gajos, G., Goland, S., Goncalvesova, E., Kang, S., Katova, T., Kosiborod, M. N., Latkovskis, G., Lee, A. P.-W., Linssen, G. C. M., Llamas-Esperón, G., Mareev, V., Martinez, F. A., Melenovský, V., Merkely, B., Nodari, S., Petrie, M. C., Saldarriaga, C. I., Saraiva, J. F. K., Sato, N., Schou, M., Sharma, K., Troughton, R., Udell, J. A., Ukkonen, H., Vardeny, O., Verma, S., von Lewinski, D., Voronkov, L., Yilmaz, M. B., Zieroth, S., Lay-Flurrie, J., van Gameren, I., Amarante, F., Kolkhof, P., & Viswanathan, P.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Cardiovascular Division, Brigham and Women’s Hospital, and Harvard Medical School, Boston (S.D.S., M.V., B.C., A.S.D.); British Heart Foundation Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow (J.J.V.M., P.S.J., A.D.H., M.C.P.), and Bayer, Reading (J.L.-F.) — both in the United Kingdom; National Heart Centre Singapore and Duke–National University of Singapore, Singapore (C.S.P.L.); University of Michigan School of Medicine, Ann Arbor (B.P.); University of Milano-Bicocca and Papa Giovanni XXIII Hospital, Bergamo (M. Senni), and the Department of Cardiology, University of Brescia, and ASST “Spedali Civili” Hospital, Brescia (S.N.) — all in Italy; Northwestern University Feinberg School of Medicine, Chicago (S.J.S.); University Medical Center Groningen, Groningen (A.A.V.), the Department of Cardiology, Hospital Group Twente, Almelo (G.C.M.L.), and Bayer, Hoofddorp (I.G.) — all in the Netherlands; Université de Lorraine, INSERM Clinical Inv...
- ORCID
- Solomon, Scott D.
- McMurray, John J.V.
- Vaduganathan, Muthiah
- Claggett, Brian
- Jhund, Pardeep S.
- Desai, Akshay S.
- Henderson, Alasdair D.
- Lam, Carolyn S.P.
- Pitt, Bertram
- Senni, Michele
- Shah, Sanjiv J.
- Voors, Adriaan A.
- Zannad, Faiez
- Abidin, Imran Zainal
- Alcocer-Gamba, Marco Antonio
- Atherton, John J.
- Bauersachs, Johann
- Chiang, Chern-En
- Chioncel, Ovidiu
- Chopra, Vijay
- Filippatos, Gerasimos
- Fonseca, Cândida
- Gajos, Grzegorz
- Goland, Sorel
- Kosiborod, Mikhail N.
- Latkovskis, Gustavs
- Lee, Alex Pui-Wai
- Linssen, Gerard C.M.
- Melenovský, Vojtěch
- Merkely, Béla
- Nodari, Savina
- Petrie, Mark C.
- Saldarriaga, Clara Inés
- Saraiva, Jose Francisco Kerr
- Sato, Naoki
- Schou, Morten
- Troughton, Richard
- Udell, Jacob A.
- Ukkonen, Heikki
- Vardeny, Orly
- Verma, Subodh
- von Lewinski, Dirk
- Voronkov, Leonid
- Zieroth, Shelley
- Kolkhof, Peter
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-10-24
- Volume
- 391
- Issue
- 16
- Pages
- 1475-1485
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4402101139
- Cited by
- 893
- References
- 21
- Citations by year
- 2026: 414 · 2025: 398 · 2024: 81
- FWCI
- 268.66
- Type
- journal article
- Language
- en
- Open access
- green
- hal.univ-lorraine.fr
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Bayer
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- finerenone, heart failure with mildly reduced ejection fraction, heart failure with preserved ejection fraction, mineralocorticoid receptor antagonists, non-steroidal mineralocorticoid receptor antagonists, cardiovascular mortality, hyperkalemia, hypokalemia, FINEARTS-HF trial, left ventricular ejection fraction, heart failure hospitalization, drug safety
- MeSH terms
- Aged, Aged, 80 and over, Mineralocorticoid Receptor Antagonists, Double-Blind Method, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Naphthyridines, Stroke Volume, Treatment Outcome, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.